Skip to main content
Fig. 1 | BMC Immunology

Fig. 1

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Fig. 1

Vaccination schedules. CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (a) or bi-weekly (b), respectively. Pre-vaccination sampling included sera and plasma. After the end of the trial period (week 16), a re-immunization was done once every 4 weeks until death, intolerance, marked disease progression or patient’s withdrawal of consent

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us